These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38613216)

  • 21. Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease.
    Daamen AR; Lipsky PE
    Ann Rheum Dis; 2024 May; 83(6):696-699. PubMed ID: 38637134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highlight of 2023: CAR T cells driving precision therapy for autoimmune disease.
    Lee AY; Reed JH
    Immunol Cell Biol; 2024 Jul; 102(6):437-440. PubMed ID: 38693765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [CAR T-cell therapy in rheumatology-What we know so far?].
    Hagen M; Wirsching A; Bohr D; Taubmann J; Müller F; Mackensen A; Grieshaber-Bouyer R; Schett G
    Z Rheumatol; 2024 Aug; 83(6):485-491. PubMed ID: 38780637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [CAR-T therapy for autoimmune diseases].
    Alcaraz-Serna A; Porret R; Trueb L; Ribi C; Seebach J; Muller YD
    Rev Med Suisse; 2024 Apr; 20(868):688-693. PubMed ID: 38568061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.
    Hassan SH; Alshahrani MY; Saleh RO; Mohammed BA; Kumar A; Almalki SG; Alkhafaji AT; Ghildiyal P; Al-Tameemi AR; Elawady A
    Med Oncol; 2024 Apr; 41(6):127. PubMed ID: 38656354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.
    Haghikia A; Schett G; Mougiakakos D
    Lancet Neurol; 2024 Jun; 23(6):615-624. PubMed ID: 38760099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus.
    Radic M; Neeli I; Marion T
    Expert Opin Biol Ther; 2022 Apr; 22(4):499-507. PubMed ID: 35089116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?
    Santamaria-Alza Y; Vasquez G
    Inflamm Res; 2021 Jun; 70(6):651-663. PubMed ID: 34018005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?
    Stojkic I; Harper L; Coss S; Kallash M; Driest K; Lamb M; Ardoin SP; Akoghlanian S
    Pediatr Rheumatol Online J; 2024 Aug; 22(1):72. PubMed ID: 39118067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
    Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
    Front Immunol; 2020; 11():603237. PubMed ID: 33324420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Future of CAR T Therapeutics to Treat Autoimmune Disorders.
    Pecher AC; Hensen L; Lengerke C; Henes J
    Mol Diagn Ther; 2024 Sep; 28(5):593-600. PubMed ID: 39078456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Off-the-shelf CAR T cells for refractory autoimmunity.
    Papatriantafyllou M
    Nat Rev Rheumatol; 2024 Sep; 20(9):527. PubMed ID: 39075289
    [No Abstract]   [Full Text] [Related]  

  • 34. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-T cell therapy in systemic lupus erythematosus and beyond: a brave new world?
    van Leuven SI; Duivenvoorden R
    Rheumatology (Oxford); 2024 May; 63(5):1192-1194. PubMed ID: 38377390
    [No Abstract]   [Full Text] [Related]  

  • 36. Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential.
    Haddadi MH; Hajizadeh-Saffar E; Khosravi-Maharlooei M; Basiri M; Negahdari B; Baharvand H
    Blood Rev; 2020 May; 41():100645. PubMed ID: 31813654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases.
    Shu J; Xie W; Chen Z; Offringa R; Hu Y; Mei H
    Med; 2024 Jun; 5(6):495-529. PubMed ID: 38608709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR T cells for infection, autoimmunity and allotransplantation.
    Maldini CR; Ellis GI; Riley JL
    Nat Rev Immunol; 2018 Oct; 18(10):605-616. PubMed ID: 30046149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR T cells: Building on the CD19 paradigm.
    Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
    Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.